Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Holly E Gurgle, Karen White & Carrie McAdam-Marx. (2016) SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vascular Health and Risk Management 12, pages 239-249.
Read now
Read now
L. H. Chuang, B. G. Verheggen, M. Charokopou, D. Gibson, S. Grandy & B. Kartman. (2016) Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. Journal of Medical Economics 19:12, pages 1127-1134.
Read now
Read now
Marisa B Schauerhamer, Holly Gurgle & Carrie McAdam-Marx. (2015) Once-weekly exenatide as a treatment for Type 2 diabetes. Expert Review of Cardiovascular Therapy 13:6, pages 611-626.
Read now
Read now
Articles from other publishers (21)
Chun-Ting Yang, Wen-Yu Yao, Huang-Tz Ou & Shihchen Kuo. (2023) Value of GLP-1 receptor agonists versus long-acting insulins for type 2 diabetes patients with and without established cardiovascular or chronic kidney diseases: A model-based cost-effectiveness analysis using real-world data. Diabetes Research and Clinical Practice 198, pages 110625.
Crossref
Crossref
Frauke Becker, Helen A. Dakin, Shelby D. Reed, Yanhong Li, José Leal, Stephanie M. Gustavson, Eric Wittbrodt, Adrian F. Hernandez, Alastair M. Gray & Rury R. Holman. (2022) Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. Diabetes Research and Clinical Practice 183, pages 109152.
Crossref
Crossref
Chen-Yi Yang, Ying-Ren Chen, Huang-Tz Ou & Shihchen Kuo. (2021) Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. Cardiovascular Diabetology 20:1.
Crossref
Crossref
M. Mata-Cases, J. Mahon, D. Mauricio, J. Franch-Nadal, J. Real & N. Hex. (2020) Improving management of glycaemic control in people with T2DM in primary care: estimation of the impact on the clinical complications and associated costs. BMC Health Services Research 20:1.
Crossref
Crossref
J. Pöhlmann, K. Norrbacka, K. S. Boye, W. J. Valentine & H. Sapin. (2020) Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy. The European Journal of Health Economics 21:8, pages 1179-1196.
Crossref
Crossref
Bhavani Shankara Bagepally, Usa Chaikledkaew, Yogesh Krishnarao Gurav, Thunyarat Anothaisintawee, Sitaporn Youngkong, Nathorn Chaiyakunapruk, Mark McEvoy, John Attia & Ammarin Thakkinstian. (2020) Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Research & Care 8:1, pages e001020.
Crossref
Crossref
Rebeca Reyes-García, Óscar Moreno-Pérez, Cristina Tejera-Pérez, Diego Fernández-García, Virginia Bellido-Castañeda, Martín López de la Torre Casares, Pedro Rozas-Moreno, José Carlos Fernández-García, Amparo Marco Martínez, Javier Escalada-San Martín, Manuel Gargallo-Fernández, Manuel Botana-López, Judith López-Fernández, José Miguel González-Clemente, Esteban Jódar-Gimeno & Pedro Mezquita-Raya. (2019) Documento de abordaje integral de la diabetes tipo 2. Endocrinología, Diabetes y Nutrición 66:7, pages 443-458.
Crossref
Crossref
Rebeca Reyes-García, Óscar Moreno-Pérez, Cristina Tejera-Pérez, Diego Fernández-García, Virginia Bellido-Castañeda, Martín López de la Torre Casares, Pedro Rozas-Moreno, José Carlos Fernández-García, Amparo Marco Martínez, Javier Escalada-San Martín, Manuel Gargallo-Fernández, Manuel Botana-López, Judith López-Fernández, José Miguel González-Clemente, Esteban Jódar-Gimeno & Pedro Mezquita-Raya. (2019) A comprehensive approach to type 2 diabetes mellitus – A recommendation document. Endocrinología, Diabetes y Nutrición (English ed.) 66:7, pages 443-458.
Crossref
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Crossref
Néboa Zozaya, Margarita Capel, Susana Simón & Alfonso Soto-González. (2019) A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031987657.
Crossref
Crossref
Ignacio Conget, Pilar Martín-Vaquero, Stéphane Roze, Isabel Elías, Cristina Pineda, María Álvarez, Alexis Delbaere & Francisco Javier Ampudia-Blasco. (2018) Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain. Endocrinología, Diabetes y Nutrición 65:7, pages 380-386.
Crossref
Crossref
Ignacio Conget, Pilar Martín-Vaquero, Stéphane Roze, Isabel Elías, Cristina Pineda, María Álvarez, Alexis Delbaere & Francisco Javier Ampudia-Blasco. (2018) Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain. Endocrinología, Diabetes y Nutrición (English ed.) 65:7, pages 380-386.
Crossref
Crossref
Charalampos Tzanetakos, Alexandra Bargiota, Georgia Kourlaba, George Gourzoulidis & Nikos Maniadakis. (2017) Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece. Clinical Drug Investigation 38:1, pages 67-77.
Crossref
Crossref
Sarah E. Holden, Christopher Ll. Morgan, Qing Qiao, Sara Jenkins-Jones, Ellen R. Berni & Craig J. Currie. (2017) Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study. Diabetes, Obesity and Metabolism 19:8, pages 1097-1105.
Crossref
Crossref
Gabriela Vega-Hernandez, Radek Wojcik & Max Schlueter. (2017) Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK. Diabetes Therapy 8:3, pages 513-530.
Crossref
Crossref
Xinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, Lei Si, William H. Herman & Philip Clarke. (2016) How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review. PharmacoEconomics 35:3, pages 319-329.
Crossref
Crossref
Asrul Akmal Shafie, Chin Hui Ng, Yui Ping Tan & Nathorn Chaiyakunapruk. (2016) Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. PharmacoEconomics 35:2, pages 141-162.
Crossref
Crossref
Yahiya Y. Syed & Paul L. McCormack. (2015) Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus. Drugs 75:10, pages 1141-1152.
Crossref
Crossref
W. M. Valencia & H. Florez. (2014) Pharmacological treatment of diabetes in older people. Diabetes, Obesity and Metabolism 16:12, pages 1192-1203.
Crossref
Crossref
Paul L. McCormack. (2014) Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus. Drugs 74:3, pages 325-351.
Crossref
Crossref
Samuel S. Grossman. (2014) Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes. Advances in Therapy 31:3, pages 247-263.
Crossref
Crossref